Peptide LexiconAll compounds

Cetrorelix: The GnRH-Blocking Decapeptide Used in IVF — What It Is, How It Works and What Its Label Shows

Cetrorelix is a synthetic ten-amino-acid peptide, a copy of the hormone GnRH with five positions changed, that blocks the GnRH receptor instead of activating it. In IVF it stops the body's own LH surge from releasing eggs too early. It has been approved in the US as Cetrotide since 2000, with generic versions from 2024.

FDA-approved (2000)GnRH antagonistFertility treatment only

Caroline S · Published 2026-11-18

Length

10 amino acids (a decapeptide), C-terminal amide; molecular weight 1,431.06 as the anhydrous free base (label); C70H92ClN17O14 (PubChem CID 25074887)

Sequence

Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2 — GnRH with positions 1, 2, 3, 6 and 10 substituted (label)

Origin

Synthetic analogue of gonadotropin-releasing hormone. Cetrotide, EMD Serono, NDA 021197, approved 2000-08-11; generic cetrorelix acetate approved from April 2024 (Drugs@FDA)

Last reviewed

2026-11-18

What is it good for?

Preventing a premature surge of luteinising hormone (LH) in women having controlled ovarian stimulation for IVF or other assisted reproduction, so that eggs are not released before they can be collected. That is its only US indication.

Illustration: An empty white ceramic mortar and pestle on a white surface, with deep green and copper reflections.
Illustration

What it is

Cetrorelix is a GnRH antagonist — a ten-amino-acid copy of the brain hormone GnRH, altered so that it blocks the hormone's receptor. The Cetrotide label describes it as "a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity," with substitutions at positions 1, 2, 3, 6 and 10:

Position Natural GnRH Cetrorelix (label)
1 pyroglutamate Ac-D-Nal (acetyl-D-3-(2'-naphthyl)alanine)
2 His D-Cpa (D-4-chlorophenylalanine)
3 Trp D-Pal (D-3-(3'-pyridyl)alanine)
4–5 Ser-Tyr Ser-Tyr
6 Gly D-Cit (D-citrulline)
7–9 Leu-Arg-Pro Leu-Arg-Pro
10 Gly-NH2 D-Ala-NH2

Five of the ten are D-amino acids, the mirror-image forms, and four (naphthylalanine, chlorophenylalanine, pyridylalanine, citrulline) are not among the twenty amino acids that make up ordinary proteins. The natural column is gonadorelin, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (PubChem synonym); the library's gonadorelin entry covers it. The label gives a molecular weight of 1,431.06; PubChem records C70H92ClN17O14 (CID 25074887).

How it works

GnRH from the hypothalamus tells the pituitary to release LH and FSH. In the middle of a natural cycle, rising oestradiol boosts GnRH and produces the LH surge that releases the egg. In IVF, several follicles are grown with injected FSH, and an early surge would release the eggs before they can be collected.

Cetrorelix competes with natural GnRH for its receptor on pituitary cells (label). The label reports:

Property Figure (label)
Start of LH suppression about 2 h after 0.25 mg (about 1 h after 3 mg)
Initial hormone flare none detected
Effect on LH v FSH more pronounced on LH
Bioavailability under the skin 85%
Half-life, one 0.25 mg dose 5.0 h (range 2.4–48.8)
Half-life, 14 daily doses 20.6 h (range 4.1–179.3)
Reversible on stopping yes

That absence of a flare is the practical difference from the GnRH agonists such as leuprolide and goserelin, which first stimulate the receptor before suppressing it. Degarelix is another antagonist, used in prostate cancer.

What the evidence shows

The label's dosing describes the standard schedule: FSH or hMG from cycle day 2 or 3, then cetrorelix 0.25 mg under the skin once daily from stimulation day 5 or 6, continued until the day of the hCG trigger. It is reported here as the label's wording, not as a protocol.

The safety set is 949 women aged 19 to 40 (mean 32) given doses from 0.1 to 5 mg:

Event Rate
Ovarian hyperstimulation syndrome, moderate or severe 3.5% (33)
Nausea 1.3% (12)
Headache 1.1% (10)

Injection-site reactions were short-lived and mild. After marketing, mild to moderate OHSS and hypersensitivity, including anaphylactoid reactions, have been reported. The label also records two stillbirths in the phase 3 studies and, in a follow-up of 316 newborns, one twin born with anencephaly.

ClinicalTrials.gov lists 143 studies naming cetrorelix, most of them comparing IVF stimulation protocols in which it is one component. A separate line, cetrorelix pamoate intramuscular injections for benign prostatic hyperplasia, reached two phase 3 trials by AEterna Zentaris (NCT00670306, 528 participants; NCT00663858, 420), completed in 2009 and 2010 with results posted. This entry did not open their comparative results, and the US label carries no prostate indication.

Where it stands

Cetrotide was approved in the US on 11 August 2000 (NDA 021197, EMD Serono), for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation — its only indication. Drugs@FDA lists generic cetrorelix acetate from Qilu, Livzon and Gland, approved between 16 and 25 April 2024. It is a prescription medicine used under a fertility specialist; the library's ganirelix entry covers the other GnRH antagonist with the same use, and hCG the trigger it is paired with.

Sources opened 2026-11-18: Cetrotide label (openFDA, effective 2025-09-22: indications, dosage, description, clinical pharmacology, pharmacokinetics, adverse reactions); Drugs@FDA NDA 021197 and ANDAs 214540, 217776, 218150; PubChem CID 25074887 and the gonadorelin record's synonyms; ClinicalTrials.gov API v2 (143 records; NCT00670306 and NCT00663858 records and results flags); PubMed E-utilities counts.

What the research shows

Blocks the premature LH surge in IVF

FDA-approved indication (Cetrotide label, effective 2025-09-22); safety set of 949 women in clinical studies, doses 0.1 to 5 mg

Acts within hours with no initial hormone flare

Label clinical pharmacology: LH suppression begins about 2 hours after 0.25 mg (1 hour after 3 mg); no initial release of gonadotropins detected

Treats an enlarged prostate

Two phase 3 trials of cetrorelix pamoate injections by AEterna Zentaris (NCT00670306, 528; NCT00663858, 420), completed 2009–2010 with results posted; no US approval for this use

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Cetrotide 0.25 mg, NDA 021197 (EMD Serono, 2000-08-11); generic cetrorelix acetate ANDAs from Qilu, Livzon and Gland approved 2024-04-16 to 2024-04-25 (Drugs@FDA via openFDA, 2026-11-18).

Trials

ClinicalTrials.gov: 143 studies name cetrorelix, most of them IVF protocol comparisons (2026-11-18).

Published record

PubMed: 576 records for cetrorelix, 80 tagged as randomised controlled trials (2026-11-18).

Frequently asked questions

What is cetrorelix?

A synthetic ten-amino-acid peptide modelled on gonadotropin-releasing hormone (GnRH), with five of its positions changed so that it blocks the GnRH receptor instead of switching it on. It is sold as Cetrotide and as generic cetrorelix acetate.

What is cetrorelix used for in IVF?

To stop a premature LH surge during ovarian stimulation. An early surge can trigger ovulation before the eggs are mature and collected; blocking GnRH at the pituitary holds LH down until the trigger injection is given.

How is cetrorelix different from leuprolide?

Both are GnRH analogues, but leuprolide is an agonist: it first stimulates the receptor and causes a hormone flare before suppression. Cetrorelix is an antagonist; its label reports suppression within hours and no initial release of gonadotropins.

How is cetrorelix different from ganirelix?

They are both decapeptide GnRH antagonists used for the same IVF purpose, with different amino-acid substitutions. The library has a separate entry for ganirelix.

What are cetrorelix's side effects?

In 949 women in clinical studies, the label lists ovarian hyperstimulation syndrome (3.5%), nausea (1.3%) and headache (1.1%), plus short-lived injection-site redness, bruising or itching. Allergic reactions including anaphylactoid reactions have been reported after marketing.

Is cetrorelix used for prostate problems?

Not in approved use. Its maker at the time tested a long-acting form, cetrorelix pamoate, in two phase 3 trials for an enlarged prostate that finished in 2009 and 2010. The US label covers fertility treatment only.